I finally pulled the trigger on ONWD

u/Imaginary_Yogurt3965 · Reddit — r/pennystocks · September 09, 2026 at 20:04 · ⬆ 1 pts  | View on Reddit ↗
AI Summary

{"summary": "Author discloses a long position in ONWARD Medical (ONWD) after H1 results, citing ARC-EX commercialization, revenue growth, cash position, and pipeline optionality in ARC-IM and ARC-BCI.", "reason": "Actionable long thesis with identifiable asset, commercial metrics, catalysts, and stated risks.", "ideas": [{"symbol": "ONWD", "direction": "long", "thesis": "Author bought ONWARD Medical after H1 results showed ARC-EX commercialization ramping: 159 systems sold/supplied in H1 2026 (up 430% YoY), ARC-EX revenue of €3.4m (up 240%), and availability in 130+ US clinics, with expansion into home use including the Veterans Affairs system. The bull case rests on ARC-EX providing near-term commercial revenue while ARC-IM (Empower BP pivotal study with 22 participants across 14 sites, plus EIGER and Parkinson's/bladder work) and ARC-BCI (seven implants) offer larger optionality if clinical results hold. Financially the company posted a €23.3m H1 operating loss but holds €81.5m cash after a €40.6m April raise plus a BlackRock facility up to €50m, giving execution runway. Main risks are continued losses and dependence on clinical and commercial execution; author plans to hold for a while.", "thesis_short": "ONWD long on ARC-EX commercialization, ARC-IM optionality", "quote": "After today’s H1 results, I finally did.", "confidence": 0.8, "sentiment": 0.7, "timeframe": "long-term hold"}], "model": "deepseek-v4-flash"}

Score 1
Full Post Text
Ideas
u/Imaginary_Yogurt3965 Reddit r/pennystocks
ONWD long on ARC-EX commercialization, ARC-IM optionality
Author bought ONWARD Medical after H1 results showed ARC-EX commercialization ramping: 159 systems sold/supplied in H1 2026 (up 430% YoY), ARC-EX revenue of €3.4m (up 240%), and availability in 130+ US clinics, with expansion into home use including the Veterans Affairs system. The bull case rests on ARC-EX providing near-term commercial revenue while ARC-IM (Empower BP pivotal study with 22 participants across 14 sites, plus EIGER and Parkinson's/bladder work) and ARC-BCI (seven implants) offer larger optionality if clinical results hold. Financially the company posted a €23.3m H1 operating loss but holds €81.5m cash after a €40.6m April raise plus a BlackRock facility up to €50m, giving execution runway. Main risks are continued losses and dependence on clinical and commercial execution; author plans to hold for a while.
More from Reddit — r/pennystocks

This Reddit post, published September 09, 2026, features u/Imaginary_Yogurt3965 discussing ONWD. 1 trade idea extracted by AI with direction and confidence scoring.

Speakers: u/Imaginary_Yogurt3965  · Tickers: ONWD